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Abstract
Background: The small intestine is a specialized compartment were close interactions take place between host,
microbes, food antigens and dietary fatty acids. Dietary fats get absorbed by epithelial cells and processed into a
range of lipoprotein particles after which they are basolaterally secreted and collected in the lymphatics. In contrast
to the colon, the small intestine is covered only by a thin mucus coat that allows for intimate interactions between
host-cells and microbes. Lipoproteins have long been recognized as protective factors in infectious diseases via the
neutralization of bacterial toxins like lipopolysaccharides. Much less attention has been given to the potential role
of lipoproteins as factors contributing to the maintenance of small intestinal immune homeostasis via modulating
bacteria-induced immune responses.
Results: Lipoproteins VLDL, LDL and HDL were found to neutralize TLR responses towards specific TLR-ligands or a
selection of gram-negative and gram-positive bacteria. Attenuation of TLR2 activity was acute and only slightly
improved by longer pre-incubation times of ligands and lipoproteins with no differences between bacterial-
lipopeptides or bacteria. In contrast, attenuation of TLR4 responses was only observed after extensive preincubation
of lipoproteins and LPS. Preincubation of bacteria and lipoproteins led only to a modest attenuation of TLR4
activity. Moreover, compared to TLR2, TLR4 activity could only be attenuated by lipoproteins over a small ligand
dose range.
Conclusions: These results demonstrate the ability of lipoproteins VLDL, LDL and HDL to inhibit TLR responses
towards bacterial-ligands and bacteria. Presence of lipoproteins was found to modulate the MAMP-induced
cytokine release by primary human monocytes measured as changes in the release of IL-6, TNFα, GM-CSF and IFNγ.
Using TLR2 and TLR4-reporter cells, lipoproteins were found to inhibit TLR responses with differences in affinity and
kinetics. These data establish a role for lipoproteins as immunoregulatory molecules, attenuating TLR-responses and
thereby positively contributing to mucosal homeostasis.
Background
Apart from regulating lipid metabolism, evidence accu-
mulates that lipoproteins are also involved in host-
microbe interactions. It is well known that infection and
inflammation induce an acute-phase response, leading to
changes in plasma lipids and lipoprotein metabolism
which in turn add to the inflammatory cycle potentially
leading to atherosclerosis [1]. In addition, it has long
been recognized that lipoproteins (i.e. chylomicrons,
very low density lipoprotein (VLDL), low density lipo-
protein (LDL) and high density lipoproteins (HDL))
interact with microbe associated molecular patterns
(MAMP). Lipoproteins play an important role in the de-
toxification of MAMPs such as lipopolysaccharide (LPS)
and lipoteichoic acid (LTA), most likely via sequestration
of MAMPs, preventing Toll-like receptor (TLR) activa-
tion and the subsequent release of proinflammatory cy-
tokines [2–6]. However, only a few studies report on the
direct interaction of lipoproteins with bacteria and how
this would affect subsequent recognition by TLRs.
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Studies in low density receptor deficient mice (LDLR-/-)
mice, which suffer from increased circulating levels of
LDL-cholesterol, showed that LDLR-/- mice survive
longer and have lower levels of circulating proinflamma-
tory cytokine concentrations after infection with the
Gram-negative bacteria Salmonella typhimurium and
Klebsiella pneumoniae [7, 8]. Part of the protective effect
of the increased circulating levels of LDL could be
explained by the sequestration of LPS, but data indicated
that the direct interaction of bacteria with lipoproteins
might prohibit attachment of bacteria to host cells, pre-
venting dissemination into the organs [8]. On the other
hand, lipoprotein binding to bacteria might promote -
infectivity of host cells as has been shown for the intra-
cellular human pathogens Chlamydia pneumoniae and
C. trachomatis [9]. Overall, the data suggests that lipo-
protein deposits on bacterial surfaces modulate host-
microbe interactions.
Previous data indicates that preincubating cells with li-
poproteins might potentiate subsequent TLR-responses,
presumably via induction of Ca2+ mobilization [10].
Moreover, incubating cells with modified lipoproteins
(i.e. oxidized LDL), which may be formed under inflam-
matory conditions, has been shown to induce TLR
activity [11]. In this study, we analyzed the effects of
lipoproteins on TLR-induced cellular activation by
bacteria. To that end, TLR-ligands or bacteria were
preincubated with lipoproteins before the addition of
cells to rule out potential TLR-enhancing activities by
lipoproteins. We further limit our studies to native lipo-
proteins to best mimic effects under homeostatic condi-
tions. We show that VLDL, LDL and HDL attenuate
TLR activity in response to Gram-positive and Gram-
negative bacteria. TLR2-activity was attenuated immedi-
ately and over a larger dose-range compared to TLR4-
activity, indicating differences in affinity and kinetics
between lipoproteins, bacteria and TLR-induced cellular
responses.
Methods
Bacterial fermentation and enumeration
Lactobacillus salivarius NutRes 283 and Bifidobacterium
breve NutRes 200 were grown at 37 °C in a 400 ml re-
actor containing MRS broth (Oxoid, Badhoevedorp, The
Netherlands) supplemented with 0.5 g/l L-cysteine for
Bifidobacteria. The pH was maintained at 6.5 by addition
of NaOH. To ensure anaerobic conditions the headspace
was flushed with N2 or a gas mixture consisting of
5 % H2, 5 % CO2 and 90 % N2 for Bifidobacteria.
Bacteria were harvested in the early stationary phase,
washed in PBS and stored in glycerol 20 % (w/v), in
aliquots at -80 °C. Cell counts were determined by
plating serial dilutions (CFU) and fluorescent micros-
copy by staining with DAPI.
Cell lines and Reagents
Cell viability reagent WST-1 was purchased from Roche
Diagnostics, Almere, The Netherlands. Human serum and
human plasma purified lipoproteins (VLDL, LDL, HDL)
and apolipoproteins (ApoA, ApoB, ApoC1, ApoC2,
ApoC3) were all purchased from Sigma-Aldrich. Human
lipoprotein deficient serum was from Merck, Amsterdam,
the Netherlands. Heat-killed Staphylococcus aureus
(HKSA), Escherichia coli (HKEB), Salmonella typhimur-
ium (HKST) were all purchased from Invivogen, Tou-
louse, France. Ultrapure LPS derived from E. coli K12 and
purified LTA from Staphylococcus aureus (both from Invi-
vogen, Toulouse, France) were used at the indicated con-
centrations. Synthetic bacterial lipopeptides Pam3CSK4,
Pam2CSK4, FSL-1 (all from EMC microcollections, Tübin-
gen, Germany) were used at the indicated concentrations.
Non-phagocytic HEK293 TLR2-TLR6, HEK293 TLR4
stable transfectants and HEK293 TLR null control cells
were purchased from Invivogen, Toulouse, France.
HEK293 TLR2-TLR6 and HEK293 TLR null transfectants
were stably transfected with the NFκB reporter plasmid
pNiFty2-Luc, HEK293 TLR4 cells contained the NFκB re-
porter pNiFty2-SEAP (Invivogen, Toulouse, France). Cells
were maintained in DMEM (Invitrogen) supplemented
10 % FBS, 4.5 g/L glucose and the appropriate antibiotics
according to the manufacturer’s protocols.
Primary monocytes
Human primary peripheral blood mononuclear cells
(PBMCs) were isolated from buffy coats obtained from
healthy blood donors at the Sanquin Bloodbank,
Nijmegen, The Netherlands. The mononuclear cell
fraction was obtained by density centrifugation of blood
diluted 1:1 in PBS using Leucosep tubes (Greiner,
Alphen a/d rijn, The Netherlands) according to the
manufacturer’s instructions. Next, 1E+06 PBMCs in
RPMI 1640 medium supplemented with 1 % heat inacti-
vated fetal calf serum were seeded in 96-well flat bottom
plates and allowed to adhere in a 5 % CO2 incubator at
37 °C. Non-adherent cells were removed and the
adherent cells were washed 3 times with 37 °C RPMI
1640 medium. The adherent cell fraction was incubated
with bacteria or bacterial ligands in stimulation assays as
described below. Supernatants were collected after 16H
and analyzed for the release of TNFα, interleukin-6,
GM-CSF and interferonγ by multiplex detection immu-
noassays (Bio-Rad, veenendaal, The Netherlands). No
cytokine release above detection level could be measured
when primary monocytes were incubated with human
serum or delipidated serum alone (data not shown).
Stimulation assays
Bacteria or bacterial ligands were either directly seeded
or pre-incubated, for 30 min unless otherwise indicated,
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into individual wells of a 96-wells plate with DMEM
supplemented with 4.5 g/L glucose and 5 % human
serum (HS), 5 % delipidated human serum (HSdelip) or
5 % HSdelip supplemented with 100 μg/ml of the lipo-
proteins (VLDL, LDL, HDL) or 5 μg/ml apolipoproteins
(ApoA, ApoB, ApoC1, ApoC2, ApoC3) where indicated.
After preincubation, 1E+05 TLR transfected cells were
added to a final volume of 100 μl/well and incubated for
16H. The following day, HEK293 TLR2-TLR6 or
HEK293 Null transfectants were analyzed for NFκB
activation by measuring luciferase content via addition
of 1 volume of the luciferase substrate: BriteLite (Perkin
Elmer, Groningen, The Netherlands) after which
Luminescence was measured. HEK293 TLR4 superna-
tants were analyzed for NFκB activity by measuring
secreted embryonic alkaline phosphatase (SEAP) activity
using QUANTI-Blue (Invivogen, Toulouse, France) after
which OD was measured using a spectrophotometer.
Bacteria were used at a ratio of 25:1 (bact:cell) unless
otherwise indicated. TNFα was used at a concentration
of 5 ng/ml. LPS was used at a concentration of 1 ng/ml
and FSL-1 at 5 ng/ml unless otherwise indicated. None
of the tested bacteria or bacterial ligands induced NFκB
expression in the HEK293 TLR null control cells (data
not shown). Cell viability was checked by adding WST-1
reagent to the cells, change in OD indicates cellular
enzyme activity and functions as a measure for cell
proliferation and viability.
Statistical analysis
Statistical analyses were performed using the Student’s
t test with the Graphpad Prism 6.02 statistical software.
Differences were considered significant at p <0.05.
Results
TLR stimulation by bacteria or TLR-specific ligands is at-
tenuated in the presence of serum lipids
Serum lipoproteins are known to bind and neutralize
bacterial ligands. However, not much is known about
how serum lipids modulate immune responses following
challenges with intact bacteria. To investigate whether
serum lipoproteins are able to modify cellular responses
to bacteria, we challenged human primary monocytes
with the gram-positive bacteria Bifidobacterium breve
and Lactobacillus salivarius, the gram-negative bacteria
Escherichia coli and Salmonella typhimurium and the
TLR2 specific ligand FSL-1 and TLR4 specific ligand
LPS in the presence of intact human serum (HS) or
human serum depleted for lipoproteins (HSdelip) and
measured cytokine release (Fig. 1 and Additional file 1).
Data indicates that TNFα, IL-6, GM-CSF and IFNγ
release were affected by the presence of serum lipopro-
teins depending on bacterial strain or TLR-ligand. Cellu-
lar responses toward bacteria are for a large part
determined by the activity of TLRs. To determine to
what extend serum lipoproteins affect surface TLR
activity we investigated the neutralization of LPS and a
selection of TLR2 specific ligands (FSL-1, Pam2CSK4,
Pam3CSK4 and LTA), by comparing the TLR activity in
HS and HSdelip using TLR reporter cells. TLR2 activity
in response to TLR2-specific ligands was significantly
inhibited over a wide dose-range in the presence of HS
compared to HSdelip (Fig. 2a and Additional file 2). To
rule out any effect of the presence or absence of serum
lipoproteins on cell growth we tested for changes in cell
proliferation and viability as described in materials and
methods. No changes in cellular conditions could be ob-
served upon culture in HS or HSdelip (Additional file 2).
TLR4 activity in response to LPS stimulation was not
differently affected by the presence of either HS or
HSdelip (Fig. 2b). Preincubating LPS for 8 h with HS or
HSdelip, before the addition of TLR4 reporter cells, led
to a attenuation of TLR4 activity observed from a dose
of 11.1 ng/ml and lower (Fig. 2c). To investigate whether
TLR2 activation following bacterial stimulation was
similarly affected, we incubated TLR2 reporter cells with
the intact bacteria S. aureus, E. coli, S. typhimurium, B.
breve and L. salivarius. Presence of serum lipids attenu-
ated TLR2 activity, suggesting a non-specific effect of
serum lipids on bacterial induced TLR2 activation
(Fig. 2d).
VLDL, LDL and HDL serum lipid-fractions attenuate bac-
terial and ligand induced TLR activity
To identify the lipid fraction in human serum inducing
the observed inhibitory effect on TLR2 activation, we
stimulated TLR2 reporter cells with B. breve and FSL-1
in the presence of VLDL, LDL or HDL fractions. All
lipid fractions attenuated TLR2 induced NFκB activity
after stimulation with B. breve or FSL-1 (Fig. 3a,b). How-
ever, differences in effectiveness between lipoprotein
fractions could be observed. VLDL was already effective
at a low concentration which did not increase with
increasing dose. In contrast, HDL and LDL clearly
showed a dose-dependent effect. To investigate whether
or not the observed effect was TLR specific we per-
formed a similar experiment using stimulation with the
cytokine TNFα. None of the lipid fractions were able to
attenuate TNFα induced NFκB activity (Fig. 3c). To
extend our findings to a selection of different bacteria,
we incubated S. aureus, S. typhimurium, E. coli, L. sali-
varius and B. breve with TLR2 reporter cells in the pres-
ence of the different serum lipid fractions. Again,
bacteria-induced TLR2 responses were attenuated in the
presence of VLDL, LDL or HDL (Fig. 4). We next inves-
tigated whether prolonged preincubation of bacteria
with the different lipoprotein fractions would even
further attenuate TLR2 responses. In addition, we
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addressed lipid preincubation effects on TLR4 activity in
response to LPS or the gram-negative bacteria E. coli.
TLR2 activity after ligation by B. breve and L. salivarius
was approximately 50 % reduced by the presence of HS
or the different lipid-fractions compared to HSdelip
while no differences could be observed between direct
incubation or preincubation (Fig. 5a,b). TLR2 activity in
response to E. coli and S. typhimurium without preincu-
bation also showed approximately 50 % inhibition how-
ever, preincubation for up to 8 h further increased the
inhibitory effect of the lipoprotein fractions most clearly
observed in the VLDL fraction (Fig. 5c,d). FSL-1 induced
TLR2 activity was approximately 75 % reduced by serum
or lipoprotein fraction without preincubation, preincu-
bation for 2 h or more led to an almost complete inhib-
ition of TLR2 activity (Fig. 5e). TLR4 activity in response
to ligation by LPS was found to decrease with preincu-
bation time, reaching approximately 40 % reduction by
HS and VLDL after 8 h of preincubation (Fig. 5f ). Prein-
cubation with LDL or HDL did not lead to a significant
reduction of TLR4 activity. Intact serum inhibited TLR4
activity in response to E. coli by approximately 50 % with
no preincubation till 60 % with 8 h of preincubation
(Fig. 5g). A minimum of 2 h of preincubation of the sep-
arate lipoprotein fractions with E. coli was necessary to
significantly reduce TLR4 activity. Overall, these results
suggest a role for VLDL, LDL and HDL in the inhibition
of TLR-induced cellular activation observed in the pres-
ence of human serum. Moreover, since non-TLR in-
duced cellular activity was not affected, VLDL, LDL and
HDL seem to specifically inhibit TLR-activity in re-
sponse to bacterial and ligand stimulation.
Apolipoproteins are not the main drivers of the TLR2
inhibitory effect
Lipoproteins VLDL, LDL, and HDL contain apolipopro-
teins as structural components. Several classes and sub-
classes exist which provide additional functions as cofac-
tors for enzymes and ligands for cell-surface receptors
[12, 13]. Previous data suggest that apolipoproteins have
a role in the attenuation of TLR-signaling after ligation
by bacterial lipoproteins [14]. To this end, we evaluated
lipid-free apolipoprotein A, B, C1, C2 and C3 for their
effect on bacterial induced TLR2 stimulation.
Fig. 1 Serum lipoproteins modulate bacteria and bacterial-ligand induced immune responses. Primary monocytes were incubated with the intact
bacteria B. breve, L. salivarius, E. coli and S. typhimurium at a ratio of 25:1 (bact:cell) or the bacterial ligands FSL-1 (100 ng/ml) or LPS (10 ng/ml).
Supernatants were collected after 16H incubation and analyzed for the release of TNFα (a), IL-6 (b), GM-CSF (c) and IFNγ (d). Values represent
mean ± SEM of 4 donors. Data is represented as percentage release compared to HS. Absolute cytokine levels are presented in Additional file 1. *:
p < 0.05 **: P < 0.01
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Fig. 2 Effect of human serum and delipidated human serum on the ability of bacterial-ligands or bacteria to induce TLR2 or TLR4 activity.
HEK-TLR2-TLR6 cells or HEK-TLR4 cells were incubated with a dose range of FSL-1 or LPS respectively in the presence of human serum (HS) or
delipidated human serum (HSdelip). FSL-1 (a) but not LPS (b) activity was inhibited by HS compared to HSdelip. c LPS was preincubated with HS
or HSdelip for 8 h before addition of HEK-TLR4 cells. LPS-activity was significantly inhibited by HS compared to HSdelip. d HEK-TLR2-TLR6 cells
were incubated with S. aureus, E. coli, S. thyphimurium, B. breve or L. salivarius in the presence of HS or HSdelip. HS significantly inhibited
S. thyphimurium, B. breve or L. salivarius induced TLR2/6 activity. Each value represents mean ± SD of triplicates. The experiment shown is
representative of three separate experiments. *: p < 0.05 **:P < 0.01 ***:P < 0.001 determined by comparison with HSdelip
Fig. 3 Effect of HSdelip or HSdelip supplemented with VLDL, LDL or HDL on TNFα, B. breve or FSL-1 induced NFκB activity. HEK-TLR2-TLR6 cells
were incubated with B. breve, FSL-1 or TNFα in the presence of HSdelip or HSdelip supplemented with a dose range of the lipoprotein fractions
HDL, LDL or VLDL. TLR2/6 activity in response to B. breve (a) or FSL-1 (b) was dose-dependently inhibited by the different lipoprotein fractions. c
None of the lipoprotein fractions inhibited the TNFα induced NFκB activity. Each value represents mean ± SD of triplicates. The experiment shown
is representative of three separate experiments. *: p < 0.05 **:P < 0.01 ***:P < 0.001 determined by comparison with HSdelip
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Apolipoprotein A (ApoA) increased TLR2 activity
against all strains tested accept for B. breve, in contrast
to apolipoprotein B (ApoB) which inhibited TLR2 activ-
ity (Fig. 6). However, we observed that the inhibitory
effect of ApoB was due to cellular toxicity (data not
shown). Lipid-free ApoB, as used in our studies, was
previously recognized to be toxic after addition to cell-
cultures [15]. Apolipoprotein C1 (ApoC1), C2 (ApoC2)
and C3 (ApoC3), showed a more strain dependent effect
on TLR2 activity. ApoC1, but not ApoC2 nor ApoC3,
slightly attenuated TLR2 activity in response to S. typhi-
murium. ApoC2 slightly enhanced TLR2 activity follow-
ing stimulation with S. typhimurium, E. coli or L.
salivarius while having no effect on stimulation by
B.breve. ApoC3 slightly enhanced TLR2 activity in
response to S. typhimurium, E. coli or L. salivarius but
this did not reach significance. Overall, apolipoproteins
by themselves are not the main drivers of the observed
attenuation of TLR-activity due to serum lipids. How-
ever, our observations suggest that apolipoproteins play
a role in bacterial induced TLR activity, but their contri-
bution to the inhibitory actions of VLDL, LDL or HDL
remains to be determined.
Discussion
Cells of the small intestine perform many functions. For
instance, small intestinal epithelial cells are critically
important in the absorbance and processing of dairy
fatty acids and a specialized subset of epithelial cells
(microfold or M-cells) line specific compartments
(Peyer’s patches) that are involved in luminal sampling.
After processing of dietary fats into lipoproteins they are
basolaterally collected in lymph ducts and move via the
mesenteric lymph into the circulation as chylomicrons,
VLDL, LDL or HDL particles [16]. Antigens are taken
up by Peyer’s patch resident antigen presenting cells and
move via the lymphatics to the mesenteric lymph node
(MLN) were, in a normal healthy and unchallenged
condition, tolerance is established [17, 18]. Microbes,
either sampled from Peyer’s patches or directly via
dendritic cell capture, are similarly carried to the MLN
which acts as a firewall and prevents further dissemin-
ation [17, 19]. Compared to the colon, the small intes-
tine is covered by a relatively thin mucus-layer that
enables direct and frequent interactions between com-
mensals, probiotics and food-borne pathogens and
mucosal immune cells [20]. Therefore, the small intestine
Fig. 4 Effect of HSdelip or HSdelip supplemented with VLDL, LDL or HDL on bacteria-induced TLR2 activity. HEK-TLR2-TLR6 cells were incubated
with S. aureus (a), E. coli (b), L. salivarius (c), S. typhimurium (d) or B. breve (e) at a ratio of 10:1 (black bars) or 25:1 (grey bars) (bact:cell) in the
presence of HS or HSdelip supplemented with the different lipoprotein fractions. HDL, LDL or VLDL significantly inhibited bacterial induced TLR2
activation. Each value represents mean ± SD of triplicates. The experiment shown is representative of three separate experiments. *:p < 0.05 **:P <
0.01 ***:P < 0.001 determined by comparison with HSdelip 10:1. $:p < 0.05 $$:P < 0.01 $$$:P < 0.001 determined by comparison with HSdelip 25:1
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can be seen as a compartment were constant interac-
tions take place between antigens (food, bacterial) and
lipoproteins. Although much is known about the inter-
action of lipoproteins with bacterial ligands, not much is
known on how lipoproteins interact with intact bacteria
and how this would affect subsequent immune
responses.
Here, we show that the presence of lipoproteins inhibit
TLR-activation in response to both specific TLR-ligands
as well as a broad selection of gram-negative as well as
gram-positive bacteria. We have shown that specific TLR-
ligands interact with lipoproteins with differences in
kinetics and affinity. For lipoproteins to inhibit TLR4
activation by LPS, extensive preincubation of LPS with
lipoproteins before the addition of cells was needed. This
is in agreement with previous data where preincubation
for at least 4 h was necessary to neutralize LPS. Moreover,
similar to our findings, neutralization of LPS was maximal
at dosages below 10 ng/ml [21]. Previous published data
demonstrated that serum lipoproteins are able to attenu-
ate TLR2-induced macrophage activation in response to
both purified LTA from Staphylococcus aureus and
recombinant bacterial lipopeptides, mimicking cell wall
fragments from Chlamydia trachomatis and Borrelia
burgdorferi. Similar to our observations, lipoprotein
neutralization of the bacterial products was accomplished
Fig. 5 Effect of HS, HSdelip or HSdelip supplemented with VLDL, LDL or HDL on the ability of bacterial-ligands or bacteria to induce TLR2 or TLR4
activity. Bacteria or bacterial ligands were preincubated for the indicated times with either HS, HSdelip (HSd) or HSdelip supplemented with the separ-
ate lipoproteins before the addition of TLR-transfected cells. TLR2 activity in response to ligation by B. breve (a) and L. salivarius (b) was attenuated by
HS or HSdelip supplemented with VLDL, LDL or HDL. No effect between the different preincubation times could be observed. TLR2 activity in response
to ligation with E. coli (c), S. thyphimurium (d) or FSL-1 (e) was attenuated by HS or HSdelip supplemented with VLDL, LDL or HDL. This effect increased
with prolonged preincubation. TLR4 activity in response to ligation with E. coli (f) or LPS (g) was attenuated by HS or HSdelip supplemented with VLDL,
LDL or HDL. This effect increased with prolonged preincubation. Each value represents mean ± SD of triplicates. The experiment shown is
representative of three separate experiments. *: p < 0.05 **:P < 0.01 ***:P < 0.001 determined by comparison with HSdelip
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without extensive preincubation [2, 14]. In the present
study, we extended our observations to include intact bac-
teria. Bacteria-induced TLR2 activity was attenuated in
the presence of intact serum, in contrast to delipidated
serum, suggesting a role for lipoproteins. The molecular
mechanisms of this process remain largely unknown. Li-
poproteins offer valuable substrates for cellular growth
and therefore a lack of lipoproteins might impact cell pro-
liferation or subsequent cellular responses. However, no
changes in cell viability or activity upon culture of the
TLR-transfectants in the presence or absence of lipopro-
teins could be observed (Additional file 2). Moreover, as
indicated by the stimulation with TNFα, non-TLR induced
responses were not inhibited by the presence of lipopro-
teins suggesting the effects are limited to TLR-induced re-
sponses (Fig. 3). Taken together, these observations
suggest that lipoproteins affect cellular responses via inter-
ference with ligand-TLR binding. Lipoprotein particles
bear no TLRs on their surface, so interactions between
bacterial ligands and lipoproteins are not governed by
ligand-receptor interactions. Rather, bacterial ligands are
thought to simply dissolve into the phospholipid coat of
the lipoprotein, sequestering the lipid part of the ligand
from insertion into the ligand-binding portion of TLRs
[3]. All lipoproteins are made up of protein, phospho-
lipids, cholesterol and triglycerides. However, only the
phospholipid content correlates to the effectiveness of lig-
and neutralization [22]. Bacterial lipopeptides, in contrast
to LPS, share structural similarities with phospholipids.
Lipopeptides have a cysteine group attached to a glycerol
subunit, while phospholipids have a phosphate group at-
tached to a glycerol subunit. In both cases two fatty acyl
chains are coupled to the glycerol subunits. We presume
that the differences in molecular make-up, with regard to
the number and make-up of fatty-acyl chains, between
LPS and LTA or lipopeptides might therefore explain the
difference in neutralization kinetics by lipoproteins. How-
ever, we could find no data substantiating this hypothesis.
It is known that the plasma proteins soluble CD14 and
LPS-binding protein (LBP) greatly facilitate LPS and LTA
neutralization by lipoproteins [2, 23, 24]. In addition to
LPS, LBP is reported to bind LTA as well as di and tri-
acylated lipopeptides [25]. Since our TLR-transfected
HEK cells constitutively express CD14, presence or ab-
sence of LBP does not explain the difference in kinetics
between TLR2 and TLR4. However, since LBP in the
Fig. 6 Effect of HSdelip or HSdelip supplemented with different apolipoproteins on the ability of bacteria to induce TLR2 activity. HEK-TLR2-TLR6
cells were incubated with S. typhimurium, E. coli, L. salivarius or B. breve at a ratio of 10:1 (black bars) or 25:1 (grey bars) (bact:cell) in the presence
of HSdelip or HSdelip supplemented with the different apolipoproteins. ApoA enhanced, while ApoB and ApoC1 reduced, S. typhimurium (a) in-
duced TLR2 activity, while ApoC2 and ApoC3 had no effect. ApoA and ApoC1-3, but not ApoB, were found to increase E.coli (b) or L.salivarius (c)
induced TLR2 activity. No effect of ApoA and ApoC1-3 could be observed on B. breve (d) induced TLR2 activity, accept for ApoB which reduced
TLR2 activity. Each value represents mean ± SD of triplicates. The experiment shown is representative of three separate experiments. . *:p < 0.05
**:P < 0.01 ***:P < 0.001 determined by comparison with HSdelip 10:1. $:p < 0.05 $$:P < 0.01 $$$:P < 0.001 determined by comparison with
HSdelip 25:1
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circulation is found attached to lipoproteins [26], absence
of LBP in delipidated HS or the different purified lipopro-
tein fractions might account for the differences between HS
and HSdelip regarding their inhibitory effect on TLR4-
activity in response to E. coli. Moreover, presence of LBP
might be more crucial in neutralization of LPS compared
to di or tri-acylated bacterial lipoproteins [14, 23]. Poten-
tially, to compensate for the lower kinetics in neutralization
of TLR4 ligands, the small intestine also locally produces
LBP and the apolipoprotein serum amyloid A (SAA) that is
known to contribute to the neutralization of gram-negative
bacteria [27, 28]. Not much is known about how lipopro-
teins interact with intact bacteria. Bacterial cell-wall constit-
uents like LPS, LTA and lipopeptides are carbohydrates or
proteins bound to a lipid tail which is buried into the cell
wall. It is therefore unlikely that the same principles that
govern the interaction between lipoproteins and bacterial
fragments equally apply to the interaction with intact bac-
teria. Lipid-free apolipoproteins play a role in bacteria-TLR
interactions with the presence of apolipoproteins increasing
TLR activity (Fig. 6). However, these findings are in appar-
ent contrast to work done by Bas et al, where it was shown
that apolipoproteins attenuate TLR-activity in response to
bacterial lipopeptides [14]. These two findings may, at first
sight, seem contradictory. However, interactions between
the hydrophobic nature of apolipoproteins and the hydro-
phic part of bacterial lipoproteins could be envisaged lead-
ing on the one hand to sequestering of bacterial products
and inhibition of TLR-activity, while on the other hand to
deposition on the bacterial cell wall, acting as ligands for
scavenger receptors that recognize apolipoproteins subse-
quently facilitating interaction with TLRs [29–31]. In sup-
port of this hypothesis, lysine residues of apoA were found
to interact with bacterial cell walls based on electrostatic
forces leading to deposition of apoA on the bacterial sur-
face [32]. Moreover, the silkworm apoB homologue, apoli-
pophorin, specifically interacts with LTA expressed on the
bacterial cell surface [33, 34]. In addition, specific peptides
derived from apoE were shown to have anti-microbial
properties most likely via binding to LPS [35]. Overall, this
indicates that lipoproteins interact with bacterial surfaces,
through their apolipoprotein content, either via electro-
static interactions or by binding to specific ligands. Interest-
ingly, mice deficient for either apoA or apoE show
differences in their microbiota composition compared to
wild type mice [36, 37]. However, it remains to be deter-
mined whether this is due to differences in the direct inter-
actions between apolipoproteins and the microbiota or
more indirectly through changes in host metabolism which
may impact microbiota composition.
Conclusions
Although lipoproteins are recognized as factors that play
a role in innate immunity, much of the research efforts
so far have focused on the role of circulating lipids and
infection [3, 5]. We have provided data indicating that li-
poproteins may also play a role in the maintenance of
intestinal homeostasis by neutralizing potential harmful
bacterial-derived ligands, as well as by modulating cellu-
lar responses towards bacteria. Using a selection of bac-
teria encompassing both gram-positive and gram-
negative bacteria as a model for non-pathogenic encoun-
ter of host-cells with bacteria, lipoproteins were found
to down modulate subsequent TLR responses to both
gram-negative as well as gram-positive bacteria, a
process recognized to be important for intestinal toler-
ance [38, 39]. These findings are relevant for our under-
standing of the immune response towards commensals
and (potential) pathogens. Furthermore, these results
may be important to consider when studying the effects
of probiotic applications, e.g. in relation to the food
matrix or dietary context in which the bacteria are sup-
plied in or when translating effects from the in vitro to
the in vivo situation.
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Additional file 1: Serum lipoproteins modulate bacteria and bacterial-
ligand induced immune responses. Primary monocytes were incubated
with the intact bacteria B. breve, L. salivarius, E. coli and S. typhimurium
at a ratio of 25:1 (bact:cell) or the bacterial ligands FSL-1 (100 ng/ml) or
LPS (10 ng/ml). Supernatants were collected after 16H incubation and
analyzed for the release of TNFα (A), IL-6 (B), GM-CSF (C) and IFNγ (D).
Values represent mean ± SEM of 4 donors. (TIF 276 kb)
Additional file 2: Effect of HS or HSdelip on ligand induced TLR activity.
HEK-TLR2-TLR6 cells were incubated with a dose range of (A)Pam3CSK4,
(B) Pam2CSK4 or (C) LTA respectively in the presence of human serum
(HS) or delipidated human serum (HSdelip). HS significantly inhibited
ligand-induced TLR2 activity when compared to HSdelip. Effect of HS or
HSdelip on cellular activity. HEK-TLR2-TLR6 cells were incubated in either
HS or HSdelip. After overnight incubation 10 μl of the WST-1 reagent was
added. (D) Change in OD was recorded over the indicated time points
(minutes). No difference in cellular activity could be observed between
HS or HSdelip. (TIF 305 kb)
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